Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
106 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Rosacea - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Rosacea - Pipeline Review, H2 2014', provides an overview of the Rosacea's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rosacea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rosacea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rosacea - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Rosacea Overview 9 Therapeutics Development 10 Pipeline Products for Rosacea - Overview 10 Pipeline Products for Rosacea - Comparative Analysis 11 Rosacea - Therapeutics under Development by Companies 12 Rosacea - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Rosacea - Products under Development by Companies 17 Rosacea - Companies Involved in Therapeutics Development 18 Allergan, Inc. 18 Valeant Pharmaceuticals International, Inc. 19 Novartis AG 20 Amorepacific Corporation 21 Galderma S.A. 22 Paratek Pharmaceuticals, Inc. 23 Celgene Corporation 24 Paloma Pharmaceuticals, Inc. 25 Foamix Ltd. 26 Gene Signal International SA 27 Cutanea Life Sciences 28 Sol-Gel Technologies Ltd. 29 Signum Biosciences, Inc. 30 Advancell 31 Celtaxsys, Inc. 32 Brickell Biotech, Inc. 33 Delenex Therapeutics AG 34 TWi Pharmaceuticals, Inc. 35 Dermira Inc. 36 Rosacea - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Mechanism of Action 42 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 oxymetazoline hydrochloride - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ivermectin - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 apremilast - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 omiganan pentahydrochloride - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 aganirsen - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 DRM-02 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 (betamethasone + calcipotriene) - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 DER-45EV - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 PAC-14028 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 PDI-320 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 AC-701 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 minocycline - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 sarecycline hydrochloride - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NS2 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 SIG-990 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 DLX-1008 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 CTX-4430 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 ANs-29 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 minocycline Gel - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 GM-1111 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 SIG-989 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 SIG-1191 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 SIG-1192 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 P-529 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Rosacea - Recent Pipeline Updates 84 Rosacea - Dormant Projects 95 Rosacea - Discontinued Products 96 Rosacea - Product Development Milestones 97 Featured News & Press Releases 97 Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 97 Mar 22, 2014: Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosacea 97 Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 98 Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 99 Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 100 Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 100 Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 101 Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 102 Feb 27, 2013: Galderma Announces Availability Of Apprilon In Canada For Treatment Of Rosacea 102 Jun 25, 2012: Flower power may be answer to itchy problem 103 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 106 Disclaimer 106
List of Tables Number of Products under Development for Rosacea, H2 2014 10 Number of Products under Development for Rosacea - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Rosacea - Pipeline by Allergan, Inc., H2 2014 18 Rosacea - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 19 Rosacea - Pipeline by Novartis AG, H2 2014 20 Rosacea - Pipeline by Amorepacific Corporation, H2 2014 21 Rosacea - Pipeline by Galderma S.A., H2 2014 22 Rosacea - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 23 Rosacea - Pipeline by Celgene Corporation, H2 2014 24 Rosacea - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 25 Rosacea - Pipeline by Foamix Ltd., H2 2014 26 Rosacea - Pipeline by Gene Signal International SA, H2 2014 27 Rosacea - Pipeline by Cutanea Life Sciences, H2 2014 28 Rosacea - Pipeline by Sol-Gel Technologies Ltd., H2 2014 29 Rosacea - Pipeline by Signum Biosciences, Inc., H2 2014 30 Rosacea - Pipeline by Advancell, H2 2014 31 Rosacea - Pipeline by Celtaxsys, Inc., H2 2014 32 Rosacea - Pipeline by Brickell Biotech, Inc., H2 2014 33 Rosacea - Pipeline by Delenex Therapeutics AG, H2 2014 34 Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2014 35 Rosacea - Pipeline by Dermira Inc., H2 2014 36 Assessment by Monotherapy Products, H2 2014 37 Assessment by Combination Products, H2 2014 38 Number of Products by Stage and Target, H2 2014 41 Number of Products by Stage and Mechanism of Action, H2 2014 44 Number of Products by Stage and Route of Administration, H2 2014 46 Number of Products by Stage and Molecule Type, H2 2014 48 Rosacea Therapeutics - Recent Pipeline Updates, H2 2014 84 Rosacea - Dormant Projects, H2 2014 95 Rosacea - Discontinued Products, H2 2014 96
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
